India Hospital Stocks 2026: Apollo, Max, Fortis & NH

India's private hospital sector has emerged as one of the most compelling structural growth stories on the NSE. Rising incomes, medical tourism, and chronic-disease prevalence are driving sustained volume growth across the four largest listed hospital chains — Apollo Hospitals (APOLLOHOSP), Max Healthcare (MAXHEALTH), Fortis Healthcare (FORTIS), and Narayana Hrudayalaya (NH). This article examines each company's latest financials, EBITDA margins, return ratios, and valuations using DocStoX data sourced from audited filings.

Sector Snapshot: Why Hospital Stocks Are in Focus

India's healthcare infrastructure gap — roughly 1.4 hospital beds per 1,000 people against the WHO recommended 3 — means private chains must expand rapidly to meet demand. All four listed majors are in active capacity-addition mode, with new hospitals and OPD clusters being commissioned across Tier 1 and Tier 2 cities. Investors are willing to pay premium multiples for this structural runway, but margin discipline separates winners from laggards.

Apollo Hospitals (APOLLOHOSP): Scale Leader with Omni-channel Moat

Apollo Hospitals is India's largest private hospital network by revenue. As of DocStoX data (audited FY26 filings), Apollo reported consolidated revenue of ₹25,228 crore and EBITDA of ₹3,769 crore, translating to an EBITDA margin of 15%. PAT stood at ₹2,003 crore with a PAT margin of 7.9%. The stock trades at ₹8,845.5, putting its market capitalisation at ₹1,27,216 crore. The 52-week range is ₹6,696.5–₹8,950.0, and the stock is near its upper band.

Return ratios are healthy: ROCE at 18% and ROE at 22.1%. Apollo's debt-to-equity of 0.9x reflects ongoing capex across its Apollo 24|7 digital health platform and new hospital wings. At a P/E of 65.5x and P/B of 13.4x, the market is pricing in multi-year earnings expansion — justified by Apollo's diversified revenue streams (hospitals + pharmacies + diagnostics + health insurance JV).

Max Healthcare (MAXHEALTH): Margin Champion of the Sector

Max Healthcare stands out for having the highest EBITDA margin among listed hospital peers — 27% on FY26 revenue of ₹8,373 crore — a level rarely achieved in capital-intensive healthcare. EBITDA came in at ₹2,243 crore, and PAT reached ₹1,442 crore (PAT margin: 17.2%). The company's debt-to-equity is a lean 0.32x, the lowest in the peer group, giving it significant headroom for acquisition-led growth (as seen with its Sahara Hospital, Lucknow deal).

At a market cap of ₹1,07,287 crore (stock price ₹1,101.3), Max trades at 74.3x P/E — a premium the market awards for superior capital efficiency. ROE is 14.8% and ROCE is 15%, which look lower than Apollo's but are distorted by the large intangibles from past acquisitions. On a cash-ROCE basis, Max's underlying operating performance is stronger. Its 52-week range of ₹903–₹1,301.7 implies the stock has retraced ~15% from the peak, potentially offering a better entry point.

Fortis Healthcare (FORTIS): Recovery Play with Expanding Margins

Fortis Healthcare has undergone a significant operational turnaround since IHH Healthcare (Malaysia) took strategic control. FY26 revenue of ₹9,128 crore with EBITDA of ₹2,085 crore gives a 23% EBITDA margin — a marked improvement from the sub-15% levels seen three years ago. PAT is ₹1,064 crore (PAT margin 11.7%), and debt-to-equity stands at 0.35x.

With a market cap of ₹72,491 crore (₹951.4/share), Fortis trades at 69x P/E. ROCE is 13% and ROE 11.3% — lower than Apollo and NH, but the direction of travel is positive. Fortis's large land bank and brownfield expansion in metros give it organic growth visibility. The stock is 14% below its 52-week high of ₹1,104.3, making it a relative value play within the sector.

Narayana Hrudayalaya (NH): High ROCE, Affordable-Care Model

Narayana Hrudayalaya pioneered the high-volume, affordable-care model in cardiac surgery under Dr Devi Shetty. This cost discipline still shows up in its return ratios: ROE of 20.9% is second only to Apollo in this peer set, even as NH is the smallest by revenue (₹7,896 crore, FY26). EBITDA was ₹1,611 crore (20% margin) and PAT was ₹806 crore (PAT margin 10.2%).

NH is at ₹1,993.2/share with a market cap of ₹40,722 crore — the most modestly valued peer at 50.6x P/E, and the only one below 55x. Debt-to-equity is 1.29x, reflecting recent capex at its Cayman Islands facility (which contributes high-margin international revenue). For investors seeking exposure to hospital stocks at a relatively lower multiple, NH offers the most attractive entry on a P/E basis while maintaining strong ROE.

Peer Comparison: Key Metrics at a Glance

Here is a side-by-side comparison of the four hospital stocks using DocStoX data as of July 2026 (audited annual filings basis):

| Company | Revenue (₹ cr) | EBITDA Margin | PAT (₹ cr) | ROCE | ROE | P/E | Mkt Cap (₹ cr) | D/E |

|---------------|---------------|---------------|------------|------|-------|-------|----------------|------|

| Apollo Hosp | 25,228 | 15% | 2,003 | 18% | 22.1% | 65.5x | 1,27,216 | 0.90 |

| Max Healthcare| 8,373 | 27% | 1,442 | 15% | 14.8% | 74.3x | 1,07,287 | 0.32 |

| Fortis | 9,128 | 23% | 1,064 | 13% | 11.3% | 69.0x | 72,491 | 0.35 |

| Narayana (NH) | 7,896 | 20% | 806 | 15% | 20.9% | 50.6x | 40,722 | 1.29 |

Key takeaways:

- Max Healthcare commands the highest EBITDA margin (27%) and lowest leverage (D/E 0.32x).

- Apollo is the revenue and market-cap leader, with the best ROE (22.1%) in the group.

- NH offers the lowest P/E (50.6x) despite strong ROE of 20.9%.

- All four peers trade at significant premium P/Es (50–75x), reflecting the sector's long-runway growth narrative.

Risks to Watch

1. **Valuation risk:** At 50–75x P/E, even modest earnings disappointments can cause sharp corrections, as Max Healthcare's ~15% pullback from its 52-week high demonstrates.

2. **Capex intensity:** New hospitals take 3–5 years to reach EBITDA breakeven, dragging near-term free cash flow. Apollo and NH both carry elevated D/E from ongoing expansions.

3. **Regulatory risk:** Government pricing caps (NPPA on stents, implants) and potential extension of cost regulation to other procedures could compress margins.

4. **Talent costs:** Specialist doctor salaries are a major cost lever; any wage inflation hits margins before bed-addition benefits are realised.

5. **Working capital:** Long receivable cycles from insurance companies and government empanelment schemes (PMJAY) can strain cash conversion.

Investment Angle

The listed hospital sector in India is a structural multi-year story with high barriers to entry (land, regulatory clearances, specialist talent). Investors typically approach it in two ways:

- **Quality + moat:** Apollo (widest ecosystem) or Max (best margins, low debt) for long-term compounding.

- **Value within the sector:** NH at 50x P/E with 20.9% ROE is the most compelling on a return-per-rupee-of-valuation basis today.

All four stocks warrant continuous monitoring of quarterly EBITDA margin trajectory and new-bed ramp-up progress as the primary operating indicators.

Bottom Line

India's private hospital sector — led by Apollo Hospitals, Max Healthcare, Fortis, and Narayana Hrudayalaya — combines structural demand tailwinds with improving profitability. EBITDA margins across the peer group range from 15% (Apollo, which also operates lower-margin pharmacy/diagnostics) to 27% (Max Healthcare). Return ratios are healthy with Apollo and NH both posting ROE above 20%. While valuations are rich (50–75x P/E), the long growth runway justifies patient investors holding these names within a diversified portfolio.

SEBI Disclaimer: This is for informational purposes only and not investment advice. Please consult a SEBI-registered advisor before investing.